What this article helps you consider
- Define the three concepts
- Distinguish dissolution from dispersion
- Select a strategy for the limiting problem
Define the three concepts
Solubility describes the amount of a substance that dissolves under specified conditions at equilibrium. Dissolution describes the rate and extent of release into a medium over time. Bioavailability concerns the rate and extent to which an active ingredient or active moiety becomes available at the relevant site, with systemic exposure commonly assessed using pharmacokinetic measurements for systemically acting products.
Temperature, pH, chemical form and medium composition influence a solubility result. Particle size, surface area, wetting, formulation structure and agitation can influence dissolution. Absorption also depends on permeability, gastrointestinal conditions and physiological processes. These distinctions determine which experiment can support which statement. R10R28R29
Distinguish dissolution from dispersion
A visually clear or well-dispersed formulation can contain colloidal structures rather than molecularly dissolved material. Nanoparticles, micelles or emulsified droplets may pass through some filters and influence an apparent solubility result. Define the analytical separation and measurement method so that the reported quantity is interpretable.
For an enabling formulation, assess the behaviour after dilution and under relevant pH transitions. A supersaturated system may initially hold a high apparent concentration and then precipitate. The duration and extent of that state can matter more than a single measurement taken immediately after preparation.
Select a strategy for the limiting problem
Particle-size reduction can increase surface area but does not necessarily raise equilibrium solubility. Salt selection, amorphous dispersions, complexation and lipid-based systems address different constraints and introduce different development questions. Select an approach using evidence about the compound and intended route rather than treating one platform as universally superior.
An amorphous system may need control of recrystallisation. A lipid formulation requires attention to dispersion, digestion and the fate of the active. A highly soluble formulation can still have limited absorption if permeability or presystemic metabolism is the dominant constraint. ICH M9 provides a defined pharmaceutical framework for certain BCS-based biowaivers; it is not a general exemption from human evidence for any enhanced formulation. R29
Design studies around the proposed claim
An in-vitro claim should name the test, conditions and comparator. For example, a hypothetical prototype could show higher apparent dissolved concentration in a defined medium after 30 minutes. That is a laboratory observation, not a measured increase in human bioavailability.
For pharmacokinetic comparisons, consider dose, comparator, fed or fasted state, study design, sampling and bioanalytical measurement. Area under the concentration–time curve, peak concentration and time to peak describe different features. If doses differ, comparisons require appropriate justification; simple dose normalisation can mislead where pharmacokinetics are nonlinear. R28
Keep exposure and efficacy separate
A greater systemic exposure does not automatically imply a proportionate increase in clinical benefit or allow an equivalent reduction in dose. Safety, dose response, site of action and active metabolites may affect interpretation. For nutrients, baseline status and homeostatic regulation can further complicate the relationship between circulating concentration and benefit.
The illustration uses a measurement map to show the boundary between in-vitro evidence, pharmacokinetics and clinical outcomes. Each level requires evidence suited to its own question. A mouth-dissolving product should not be described as delivering meaningful buccal absorption unless that route has been demonstrated for the formulation.
Three separate evidence questions
Solubility and dissolution describe behaviour under specified laboratory conditions.
Conceptual illustration. Select a topic to explore its role. The visual does not establish formulation performance or prescribe universal regulatory requirements.
Build a defensible development narrative
State the limitation being addressed, the formulation mechanism proposed and the evidence generated so far. Report comparator identity, test conditions, dose and uncertainty when making numerical claims. Use product-specific human evidence for human absorption claims and appropriately designed outcome studies for efficacy claims.
Stabicon can support formulation screening and analytical characterisation that identify promising delivery approaches and the next evidence needed. This keeps scientific development and commercial communication aligned with what the data actually establish.
References & further reading
Read the source in its stated scope. Requirements, amendments and compendial editions depend on the product and target market. Draft guidance is identified separately.
- R10FDA Dissolution Testing of Immediate Release Solid Oral Dosage Forms
Final guidance, 1997. Pharmaceutical dissolution and profile comparison principles.
- R28FDA Bioavailability Studies Submitted in NDAs or INDs General Considerations
Final guidance, April 2022. Pharmaceutical bioavailability study considerations.
- R29ICH M9 Biopharmaceutics Classification System Based Biowaivers
Final guideline, 2019. Eligibility and conditions apply; not a universal waiver of human studies.
- R30FDA Assessing the Effects of Food on Drugs in INDs and NDAs
FDA guidance page. Food-effect study considerations; use the current document for the relevant programme.
From insight to a defined programme
Bring your next technical question.
Share your formulation, testing objective or development challenge. Stabicon can review the context and define a suitable scope of work.
Discuss this topic with Stabicon






